Julia A. Elvin

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• LINE-1 retrotransposition is a recurrent cause of <i>MET</i> exon 14 skipping in cancer

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-02-20

• Supplementary Figure S3 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

  2026-02-17

• Data from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

  2026-02-17

• Supplementary Table S2 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

  2026-02-17

• Supplementary Figure S1 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

  2026-02-17

• Supplementary Figure S2 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

  2026-02-17

• Supplementary Figure S4 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

  2026-02-17

• Supplementary Table S1 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

  2026-02-17

• Phenotypic POLE Variant Classification Identifies Patients Who May Have Favorable Prognosis and Benefit from Immunotherapy

  Journal of Molecular Diagnostics · 2026-01-02

• Emergence of <i>BRCA</i> Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications

  Cancer Medicine · 2026-01-01

• Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

  Clinical Cancer Research · 2025-12-04 · 1 citations

• Analytical validation of a homologous recombination deficiency signature (HRDsig) in pan-tumor tissue samples

  PLoS ONE · 2025-11-17 · 2 citations

• Comprehensive genomic profiling of folate receptor 1-positive ovarian cancer

  Gynecologic Oncology · 2025-09-01

• 157P Homologous recombination signature (HRDsig) in non-small cell lung cancer (NSCLC): Implications for PARP inhibitor (PARPi) treatment

  Annals of Oncology · 2025-09-01

• 1146P Genomic landscape of HRD signature (HRDsig), CCNE1 amplified (amp) and ERBB2 altered (alt) ovarian cancers (OC)

  Annals of Oncology · 2025-09-01

• Homozygous loss of homologous repair genes and durable benefit from poly (ADP-ribose) polymerase inhibitors maintenance for patients with ovarian cancer

  Gynecologic Oncology · 2025-09-01

• 1936P Genomic alterations (GA) in TP53 including the targetable TP53 Y220C mutation in clinically advanced non-small cell lung cancer (CANSCLC)

  Annals of Oncology · 2025-09-01

• Concordance between Foundation Medicine homologous recombination deficiency signature and Myriad genomic instability score

  Gynecologic Oncology · 2025-09-01

• Association of a homologous recombination deficiency signature with oncologic outcomes in advanced endometrial cancer

  Gynecologic Oncology · 2025-09-01

• Correction: Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice

  Clinical Cancer Research · 2025-08-14 · 1 citations